NURIX THERAPEUTICS, INC. Operating Cash Flow
NURIX THERAPEUTICS, INC. (NRIX) reported Operating Cash Flow of -$168.49 million for the 6-month period ending 2026-05-31, per its 10-Q filed 2026-07-09.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-07-09
- NURIX THERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2026-05-31 was -$96.57M.
- NURIX THERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2026-02-28 was -$71.91M.
- NURIX THERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2025-11-30 was -$67.83M.
- NURIX THERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2025-08-31 was -$57.38M.
- NURIX THERAPEUTICS, INC. net cash provided by (used in) operating activities for fiscal 2025 was -$249.47M.
- NURIX THERAPEUTICS, INC. net cash provided by (used in) operating activities for fiscal 2024 was -$172.58M.
- NURIX THERAPEUTICS, INC. net cash provided by (used in) operating activities for fiscal 2023 was -$81.36M.
- NURIX THERAPEUTICS, INC. net cash provided by (used in) operating activities for fiscal 2022 was -$159.81M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-05-31 | -$96.57M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-09 | -$168.49M 10-Q · filed 2026-07-09 | -$236.32M derived: sum of 3 quarters · filed 2026-07-09 | -$293.70M derived: sum of 4 quarters · filed 2026-07-09 |
| 2026-02-28 | -$71.91M 10-Q · filed 2026-04-08 | -$139.75M derived: sum of 2 quarters · filed 2026-04-08 | -$197.13M derived: sum of 3 quarters · filed 2026-04-08 | -$260.29M derived: sum of 4 quarters · filed 2026-07-09 |
| 2025-11-30 | -$67.83M derived: 10-K 12 month − 10-Q 9 month · filed 2026-01-28 | -$125.22M derived: sum of 2 quarters · filed 2026-01-28 | -$188.38M derived: sum of 3 quarters · filed 2026-07-09 | -$249.47M 10-K · filed 2026-01-28 |
| 2025-08-31 | -$57.38M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-09 | -$120.55M derived: sum of 2 quarters · filed 2026-07-09 | -$181.63M 10-Q · filed 2025-10-09 | -$230.38M derived: sum of 4 quarters · filed 2026-07-09 |
| 2025-05-31 | -$63.16M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-09 | -$124.25M 10-Q · filed 2026-07-09 | -$173.00M derived: sum of 3 quarters · filed 2026-07-09 | -$215.18M derived: sum of 4 quarters · filed 2026-07-09 |
| 2025-02-28 | -$61.09M 10-Q · filed 2026-04-08 | -$109.84M derived: sum of 2 quarters · filed 2026-04-08 | -$152.01M derived: sum of 3 quarters · filed 2026-04-08 | -$191.72M derived: sum of 4 quarters · filed 2026-04-08 |
| 2024-11-30 | -$48.75M derived: 10-K 12 month − 10-Q 9 month · filed 2026-01-28 | -$90.93M derived: sum of 2 quarters · filed 2026-01-28 | -$130.63M derived: sum of 3 quarters · filed 2026-01-28 | -$172.58M 10-K · filed 2026-01-28 |
| 2024-08-31 | -$42.18M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-09 | -$81.88M derived: sum of 2 quarters · filed 2025-10-09 | -$123.83M 10-Q · filed 2025-10-09 | -$97.14M derived: sum of 4 quarters · filed 2026-01-28 |
| 2024-05-31 | -$39.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-09 | -$81.66M 10-Q · filed 2025-07-09 | -$54.97M derived: sum of 3 quarters · filed 2026-01-28 | -$96.10M derived: sum of 4 quarters · filed 2026-01-28 |
| 2024-02-29 | -$41.95M 10-Q · filed 2025-04-08 | -$15.26M derived: sum of 2 quarters · filed 2026-01-28 | -$56.40M derived: sum of 3 quarters · filed 2026-01-28 | -$74.86M derived: sum of 4 quarters · filed 2026-01-28 |
| 2023-11-30 | $26.69M derived: 10-K 12 month − 10-Q 9 month · filed 2026-01-28 | -$14.44M derived: sum of 2 quarters · filed 2026-01-28 | -$32.91M derived: sum of 3 quarters · filed 2026-01-28 | -$81.36M 10-K · filed 2026-01-28 |
| 2023-08-31 | -$41.13M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-11 | -$59.60M derived: sum of 2 quarters · filed 2024-10-11 | -$108.05M 10-Q · filed 2024-10-11 | -$146.01M derived: sum of 4 quarters · filed 2025-01-28 |
| 2023-05-31 | -$18.47M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-11 | -$66.92M 10-Q · filed 2024-07-11 | -$104.88M derived: sum of 3 quarters · filed 2025-01-28 | -$151.18M derived: sum of 4 quarters · filed 2025-01-28 |
| 2023-02-28 | -$48.45M 10-Q · filed 2024-04-10 | -$86.41M derived: sum of 2 quarters · filed 2025-01-28 | -$132.72M derived: sum of 3 quarters · filed 2025-01-28 | -$165.63M derived: sum of 4 quarters · filed 2025-01-28 |
| 2022-11-30 | -$37.95M derived: 10-K 12 month − 10-Q 9 month · filed 2025-01-28 | -$84.26M derived: sum of 2 quarters · filed 2025-01-28 | -$117.18M derived: sum of 3 quarters · filed 2025-01-28 | -$159.81M 10-K · filed 2025-01-28 |
| 2022-08-31 | -$46.31M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-12 | -$79.22M derived: sum of 2 quarters · filed 2023-10-12 | -$121.85M 10-Q · filed 2023-10-12 | -$152.76M derived: sum of 4 quarters · filed 2023-10-12 |
| 2022-05-31 | -$32.91M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-07-13 | -$75.54M 10-Q · filed 2023-07-13 | -$106.45M derived: sum of 3 quarters · filed 2023-07-13 | -$136.43M derived: sum of 4 quarters · filed 2023-07-13 |
| 2022-02-28 | -$42.63M 10-Q · filed 2023-04-13 | -$73.54M derived: sum of 2 quarters · filed 2023-04-13 | -$103.51M derived: sum of 3 quarters · filed 2023-04-13 | -$135.05M derived: sum of 4 quarters · filed 2023-04-13 |
| 2021-11-30 | -$30.91M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-09 | -$60.88M derived: sum of 2 quarters · filed 2023-02-09 | -$92.42M derived: sum of 3 quarters · filed 2023-02-09 | -$84.36M 10-K · filed 2023-02-09 |
| 2021-08-31 | -$29.97M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-06 | -$61.51M derived: sum of 2 quarters · filed 2022-10-06 | -$53.45M 10-Q · filed 2022-10-06 | -$73.94M derived: sum of 4 quarters · filed 2022-10-06 |
| 2021-05-31 | -$31.54M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-07-07 | -$23.48M 10-Q · filed 2022-07-07 | -$43.96M derived: sum of 3 quarters · filed 2022-07-07 | -$50.10M derived: sum of 4 quarters · filed 2022-07-07 |
| 2021-02-28 | $8.05M 10-Q · filed 2022-04-08 | -$12.43M derived: sum of 2 quarters · filed 2022-04-08 | -$18.57M derived: sum of 3 quarters · filed 2022-04-08 | -$33.00M derived: sum of 4 quarters · filed 2022-04-08 |
| 2020-11-30 | -$20.48M derived: 10-K 12 month − 10-Q 9 month · filed 2022-01-28 | -$26.62M derived: sum of 2 quarters · filed 2022-01-28 | -$41.05M derived: sum of 3 quarters · filed 2022-01-28 | -$80.00K 10-K · filed 2022-01-28 |
| 2020-08-31 | -$6.14M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-14 | -$20.57M derived: sum of 2 quarters · filed 2021-10-14 | $20.40M 10-Q · filed 2021-10-14 | $7.65M derived: sum of 4 quarters · filed 2022-01-28 |
| 2020-05-31 | -$14.43M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-13 | $26.54M 10-Q · filed 2021-07-13 | $13.79M derived: sum of 3 quarters · filed 2022-01-28 | |
| 2020-02-29 | $40.97M 10-Q · filed 2021-04-13 | $28.22M derived: sum of 2 quarters · filed 2022-01-28 | ||
| 2019-11-30 | -$12.75M derived: 10-K 12 month − 10-Q 9 month · filed 2022-01-28 | $601.00K 10-K · filed 2022-01-28 | ||
| 2019-08-31 | $13.35M 10-Q · filed 2020-10-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |